BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34675197)

  • 1. Calibration-free NGS quantitation of mutations below 0.01% VAF.
    Dai P; Wu LR; Chen SX; Wang MX; Cheng LY; Zhang JX; Hao P; Yao W; Zarka J; Issa GC; Kwong L; Zhang DY
    Nat Commun; 2021 Oct; 12(1):6123. PubMed ID: 34675197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
    Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
    J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing.
    Song P; Chen SX; Yan YH; Pinto A; Cheng LY; Dai P; Patel AA; Zhang DY
    Nat Biomed Eng; 2021 Jul; 5(7):690-701. PubMed ID: 33941896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
    Patel SS; Pinkus GS; Ritterhouse LL; Segal JP; Dal Cin P; Restrepo T; Harris MH; Stone RM; Hasserjian RP; Weinberg OK
    Am J Hematol; 2019 Aug; 94(8):921-928. PubMed ID: 31148220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
    Patkar N; Kakirde C; Shaikh AF; Salve R; Bhanshe P; Chatterjee G; Rajpal S; Joshi S; Chaudhary S; Kodgule R; Ghoghale S; Deshpande N; Shetty D; Khizer SH; Jain H; Bagal B; Menon H; Khattry N; Sengar M; Tembhare P; Subramanian P; Gujral S
    Leukemia; 2021 May; 35(5):1392-1404. PubMed ID: 33558666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
    Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
    PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
    Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
    Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
    Ritterhouse LL; Parilla M; Zhen CJ; Wurst MN; Puranik R; Henderson CM; Joudeh NZ; Hartley MJ; Haridas R; Wanjari P; Furtado LV; Kadri S; Segal JP
    Mol Diagn Ther; 2019 Dec; 23(6):791-802. PubMed ID: 31673932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
    Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
    Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Tube qPCR Detection and Quantitation of Hotspot Mutations Down to 0.01% Variant Allele Fraction.
    Zhang K; Rodriguez L; Cheng LY; Wang M; Zhang DY
    Anal Chem; 2022 Jan; 94(2):934-943. PubMed ID: 34932306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.
    Blewett T; Rhoades J; Liu R; Xiong K; Sridhar S; Crnjac A; Cheng J; Lawless AR; Frederick DT; Flaherty KT; Makrigiorgos GM; Adalsteinsson VA
    Clin Chem; 2024 Feb; 70(2):434-443. PubMed ID: 38069911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).
    Vanni I; Casula M; Pastorino L; Manca A; Dalmasso B; Andreotti V; Pisano M; Colombino M; ; Pfeffer U; Tanda ET; Rozzo C; Paliogiannis P; Cossu A; Ghiorzo P; Palmieri G;
    Diagn Pathol; 2020 Dec; 15(1):143. PubMed ID: 33317587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
    Cheng LY; Haydu LE; Song P; Nie J; Tetzlaff MT; Kwong LN; Gershenwald JE; Davies MA; Zhang DY
    Sci Rep; 2021 Apr; 11(1):9043. PubMed ID: 33907234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing.
    Abelson S; Zeng AGX; Nofech-Mozes I; Wang TT; Ng SWK; Minden MD; Pugh TJ; Awadalla P; Shlush LI; Murphy T; Chan SM; Dick JE; Bratman SV
    Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33298453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
    N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.